Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY)
PMID: 38788861
Source: Gastroenterology
Publication date:
2025-07-24
Year:
2024
Abstract
NULL